nodes	percent_of_prediction	percent_of_DWPC	metapath
Darifenacin—CYP3A4—bone cancer	0.891	1	CbGaD
Darifenacin—Obstructive airways disorder—Methotrexate—bone cancer	0.00377	0.0349	CcSEcCtD
Darifenacin—Infection—Carboplatin—bone cancer	0.00189	0.0174	CcSEcCtD
Darifenacin—Ulcerative stomatitis—Methotrexate—bone cancer	0.00185	0.0171	CcSEcCtD
Darifenacin—Ulcerative stomatitis—Epirubicin—bone cancer	0.00174	0.016	CcSEcCtD
Darifenacin—Pain—Carboplatin—bone cancer	0.00162	0.015	CcSEcCtD
Darifenacin—Ulcerative stomatitis—Doxorubicin—bone cancer	0.00161	0.0148	CcSEcCtD
Darifenacin—Cerebrovascular accident—Cisplatin—bone cancer	0.00116	0.0107	CcSEcCtD
Darifenacin—Face oedema—Cisplatin—bone cancer	0.00109	0.0101	CcSEcCtD
Darifenacin—Breast disorder—Cisplatin—bone cancer	0.00102	0.00946	CcSEcCtD
Darifenacin—Aspartate aminotransferase increased—Cisplatin—bone cancer	0.00102	0.00943	CcSEcCtD
Darifenacin—Thinking abnormal—Epirubicin—bone cancer	0.000875	0.00809	CcSEcCtD
Darifenacin—Cough increased—Epirubicin—bone cancer	0.000875	0.00809	CcSEcCtD
Darifenacin—Vaginal inflammation—Methotrexate—bone cancer	0.000856	0.00791	CcSEcCtD
Darifenacin—Stomatitis—Cisplatin—bone cancer	0.000851	0.00786	CcSEcCtD
Darifenacin—Thinking abnormal—Doxorubicin—bone cancer	0.00081	0.00749	CcSEcCtD
Darifenacin—Cough increased—Doxorubicin—bone cancer	0.00081	0.00749	CcSEcCtD
Darifenacin—Vaginal infection—Methotrexate—bone cancer	0.000808	0.00747	CcSEcCtD
Darifenacin—Vaginal inflammation—Epirubicin—bone cancer	0.000801	0.00741	CcSEcCtD
Darifenacin—Mouth ulceration—Methotrexate—bone cancer	0.000774	0.00716	CcSEcCtD
Darifenacin—Bladder pain—Methotrexate—bone cancer	0.000774	0.00716	CcSEcCtD
Darifenacin—Urinary tract disorder—Cisplatin—bone cancer	0.000774	0.00715	CcSEcCtD
Darifenacin—Urethral disorder—Cisplatin—bone cancer	0.000768	0.0071	CcSEcCtD
Darifenacin—Vaginal infection—Epirubicin—bone cancer	0.000757	0.00699	CcSEcCtD
Darifenacin—Visual impairment—Cisplatin—bone cancer	0.000755	0.00698	CcSEcCtD
Darifenacin—Vaginal inflammation—Doxorubicin—bone cancer	0.000742	0.00685	CcSEcCtD
Darifenacin—Dry eye—Epirubicin—bone cancer	0.00074	0.00684	CcSEcCtD
Darifenacin—Eye disorder—Cisplatin—bone cancer	0.000732	0.00677	CcSEcCtD
Darifenacin—Mouth ulceration—Epirubicin—bone cancer	0.000725	0.0067	CcSEcCtD
Darifenacin—Bladder pain—Epirubicin—bone cancer	0.000725	0.0067	CcSEcCtD
Darifenacin—Mediastinal disorder—Cisplatin—bone cancer	0.000706	0.00653	CcSEcCtD
Darifenacin—Vaginal infection—Doxorubicin—bone cancer	0.0007	0.00647	CcSEcCtD
Darifenacin—Abnormal vision—Epirubicin—bone cancer	0.000699	0.00646	CcSEcCtD
Darifenacin—Mental disability—Epirubicin—bone cancer	0.000695	0.00643	CcSEcCtD
Darifenacin—Dry eye—Doxorubicin—bone cancer	0.000685	0.00633	CcSEcCtD
Darifenacin—Flatulence—Cisplatin—bone cancer	0.000672	0.00621	CcSEcCtD
Darifenacin—Mouth ulceration—Doxorubicin—bone cancer	0.00067	0.0062	CcSEcCtD
Darifenacin—Bladder pain—Doxorubicin—bone cancer	0.00067	0.0062	CcSEcCtD
Darifenacin—Visual disturbance—Methotrexate—bone cancer	0.000656	0.00606	CcSEcCtD
Darifenacin—Abnormal vision—Doxorubicin—bone cancer	0.000647	0.00598	CcSEcCtD
Darifenacin—Mental disability—Doxorubicin—bone cancer	0.000643	0.00595	CcSEcCtD
Darifenacin—Vision blurred—Cisplatin—bone cancer	0.000643	0.00594	CcSEcCtD
Darifenacin—Cerebrovascular accident—Methotrexate—bone cancer	0.000634	0.00586	CcSEcCtD
Darifenacin—Cerebrovascular accident—Epirubicin—bone cancer	0.000594	0.00549	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000577	0.00533	CcSEcCtD
Darifenacin—Breast disorder—Methotrexate—bone cancer	0.000562	0.00519	CcSEcCtD
Darifenacin—Face oedema—Epirubicin—bone cancer	0.000562	0.00519	CcSEcCtD
Darifenacin—Oedema—Cisplatin—bone cancer	0.000557	0.00515	CcSEcCtD
Darifenacin—Anaphylactic shock—Cisplatin—bone cancer	0.000557	0.00515	CcSEcCtD
Darifenacin—Infection—Cisplatin—bone cancer	0.000553	0.00511	CcSEcCtD
Darifenacin—Cerebrovascular accident—Doxorubicin—bone cancer	0.000549	0.00508	CcSEcCtD
Darifenacin—Nervous system disorder—Cisplatin—bone cancer	0.000546	0.00505	CcSEcCtD
Darifenacin—Tachycardia—Cisplatin—bone cancer	0.000543	0.00502	CcSEcCtD
Darifenacin—Skin disorder—Cisplatin—bone cancer	0.000541	0.005	CcSEcCtD
Darifenacin—Hyperhidrosis—Cisplatin—bone cancer	0.000538	0.00497	CcSEcCtD
Darifenacin—Dry skin—Epirubicin—bone cancer	0.000533	0.00493	CcSEcCtD
Darifenacin—Breast disorder—Epirubicin—bone cancer	0.000526	0.00486	CcSEcCtD
Darifenacin—Aspartate aminotransferase increased—Epirubicin—bone cancer	0.000524	0.00484	CcSEcCtD
Darifenacin—Face oedema—Doxorubicin—bone cancer	0.00052	0.0048	CcSEcCtD
Darifenacin—Alanine aminotransferase increased—Epirubicin—bone cancer	0.000513	0.00474	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000507	0.00469	CcSEcCtD
Darifenacin—Influenza—Epirubicin—bone cancer	0.000503	0.00465	CcSEcCtD
Darifenacin—Dyspnoea—Cisplatin—bone cancer	0.000496	0.00459	CcSEcCtD
Darifenacin—Erectile dysfunction—Methotrexate—bone cancer	0.000495	0.00457	CcSEcCtD
Darifenacin—Dry skin—Doxorubicin—bone cancer	0.000493	0.00456	CcSEcCtD
Darifenacin—Breast disorder—Doxorubicin—bone cancer	0.000486	0.0045	CcSEcCtD
Darifenacin—Aspartate aminotransferase increased—Doxorubicin—bone cancer	0.000485	0.00448	CcSEcCtD
Darifenacin—Bronchitis—Epirubicin—bone cancer	0.000484	0.00447	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Cisplatin—bone cancer	0.000481	0.00444	CcSEcCtD
Darifenacin—Infestation NOS—Methotrexate—bone cancer	0.000479	0.00443	CcSEcCtD
Darifenacin—Infestation—Methotrexate—bone cancer	0.000479	0.00443	CcSEcCtD
Darifenacin—Pain—Cisplatin—bone cancer	0.000476	0.0044	CcSEcCtD
Darifenacin—Alanine aminotransferase increased—Doxorubicin—bone cancer	0.000475	0.00439	CcSEcCtD
Darifenacin—Stomatitis—Methotrexate—bone cancer	0.000467	0.00432	CcSEcCtD
Darifenacin—Influenza—Doxorubicin—bone cancer	0.000465	0.0043	CcSEcCtD
Darifenacin—Sweating—Methotrexate—bone cancer	0.000459	0.00424	CcSEcCtD
Darifenacin—Feeling abnormal—Cisplatin—bone cancer	0.000459	0.00424	CcSEcCtD
Darifenacin—Weight increased—Epirubicin—bone cancer	0.000458	0.00423	CcSEcCtD
Darifenacin—Infestation—Epirubicin—bone cancer	0.000448	0.00414	CcSEcCtD
Darifenacin—Infestation NOS—Epirubicin—bone cancer	0.000448	0.00414	CcSEcCtD
Darifenacin—Bronchitis—Doxorubicin—bone cancer	0.000447	0.00414	CcSEcCtD
Darifenacin—Stomatitis—Epirubicin—bone cancer	0.000437	0.00404	CcSEcCtD
Darifenacin—Urinary tract infection—Epirubicin—bone cancer	0.000436	0.00403	CcSEcCtD
Darifenacin—Sweating—Epirubicin—bone cancer	0.00043	0.00397	CcSEcCtD
Darifenacin—Pharyngitis—Methotrexate—bone cancer	0.000427	0.00394	CcSEcCtD
Darifenacin—Urinary tract disorder—Methotrexate—bone cancer	0.000425	0.00393	CcSEcCtD
Darifenacin—Weight increased—Doxorubicin—bone cancer	0.000423	0.00391	CcSEcCtD
Darifenacin—Urethral disorder—Methotrexate—bone cancer	0.000422	0.0039	CcSEcCtD
Darifenacin—Sinusitis—Epirubicin—bone cancer	0.000421	0.00389	CcSEcCtD
Darifenacin—Infestation NOS—Doxorubicin—bone cancer	0.000415	0.00383	CcSEcCtD
Darifenacin—Infestation—Doxorubicin—bone cancer	0.000415	0.00383	CcSEcCtD
Darifenacin—Visual impairment—Methotrexate—bone cancer	0.000414	0.00383	CcSEcCtD
Darifenacin—Hypersensitivity—Cisplatin—bone cancer	0.00041	0.00379	CcSEcCtD
Darifenacin—Erythema multiforme—Methotrexate—bone cancer	0.000407	0.00376	CcSEcCtD
Darifenacin—Stomatitis—Doxorubicin—bone cancer	0.000404	0.00374	CcSEcCtD
Darifenacin—Rhinitis—Epirubicin—bone cancer	0.000403	0.00373	CcSEcCtD
Darifenacin—Urinary tract infection—Doxorubicin—bone cancer	0.000403	0.00373	CcSEcCtD
Darifenacin—Eye disorder—Methotrexate—bone cancer	0.000402	0.00371	CcSEcCtD
Darifenacin—Asthenia—Cisplatin—bone cancer	0.000399	0.00369	CcSEcCtD
Darifenacin—Pharyngitis—Epirubicin—bone cancer	0.000399	0.00369	CcSEcCtD
Darifenacin—Sweating—Doxorubicin—bone cancer	0.000398	0.00368	CcSEcCtD
Darifenacin—Urinary tract disorder—Epirubicin—bone cancer	0.000397	0.00367	CcSEcCtD
Darifenacin—Oedema peripheral—Epirubicin—bone cancer	0.000396	0.00366	CcSEcCtD
Darifenacin—Urethral disorder—Epirubicin—bone cancer	0.000394	0.00365	CcSEcCtD
Darifenacin—Angiopathy—Methotrexate—bone cancer	0.00039	0.00361	CcSEcCtD
Darifenacin—Sinusitis—Doxorubicin—bone cancer	0.000389	0.0036	CcSEcCtD
Darifenacin—Visual impairment—Epirubicin—bone cancer	0.000388	0.00358	CcSEcCtD
Darifenacin—Mediastinal disorder—Methotrexate—bone cancer	0.000388	0.00358	CcSEcCtD
Darifenacin—Diarrhoea—Cisplatin—bone cancer	0.000381	0.00352	CcSEcCtD
Darifenacin—Erythema multiforme—Epirubicin—bone cancer	0.00038	0.00352	CcSEcCtD
Darifenacin—Mental disorder—Methotrexate—bone cancer	0.000377	0.00348	CcSEcCtD
Darifenacin—Eye disorder—Epirubicin—bone cancer	0.000376	0.00348	CcSEcCtD
Darifenacin—Rhinitis—Doxorubicin—bone cancer	0.000373	0.00345	CcSEcCtD
Darifenacin—Pharyngitis—Doxorubicin—bone cancer	0.00037	0.00342	CcSEcCtD
Darifenacin—Urinary tract disorder—Doxorubicin—bone cancer	0.000368	0.0034	CcSEcCtD
Darifenacin—Oedema peripheral—Doxorubicin—bone cancer	0.000367	0.00339	CcSEcCtD
Darifenacin—Dysgeusia—Methotrexate—bone cancer	0.000367	0.00339	CcSEcCtD
Darifenacin—Angiopathy—Epirubicin—bone cancer	0.000365	0.00337	CcSEcCtD
Darifenacin—Urethral disorder—Doxorubicin—bone cancer	0.000365	0.00337	CcSEcCtD
Darifenacin—Mediastinal disorder—Epirubicin—bone cancer	0.000363	0.00335	CcSEcCtD
Darifenacin—Back pain—Methotrexate—bone cancer	0.000362	0.00335	CcSEcCtD
Darifenacin—Visual impairment—Doxorubicin—bone cancer	0.000359	0.00332	CcSEcCtD
Darifenacin—Vomiting—Cisplatin—bone cancer	0.000354	0.00327	CcSEcCtD
Darifenacin—Vision blurred—Methotrexate—bone cancer	0.000353	0.00326	CcSEcCtD
Darifenacin—Mental disorder—Epirubicin—bone cancer	0.000353	0.00326	CcSEcCtD
Darifenacin—Erythema multiforme—Doxorubicin—bone cancer	0.000352	0.00325	CcSEcCtD
Darifenacin—Rash—Cisplatin—bone cancer	0.000351	0.00324	CcSEcCtD
Darifenacin—Dermatitis—Cisplatin—bone cancer	0.000351	0.00324	CcSEcCtD
Darifenacin—Eye disorder—Doxorubicin—bone cancer	0.000348	0.00322	CcSEcCtD
Darifenacin—Flatulence—Epirubicin—bone cancer	0.000345	0.00319	CcSEcCtD
Darifenacin—Dysgeusia—Epirubicin—bone cancer	0.000343	0.00317	CcSEcCtD
Darifenacin—Back pain—Epirubicin—bone cancer	0.000339	0.00313	CcSEcCtD
Darifenacin—Angiopathy—Doxorubicin—bone cancer	0.000338	0.00312	CcSEcCtD
Darifenacin—Mediastinal disorder—Doxorubicin—bone cancer	0.000336	0.0031	CcSEcCtD
Darifenacin—Nausea—Cisplatin—bone cancer	0.000331	0.00306	CcSEcCtD
Darifenacin—Vision blurred—Epirubicin—bone cancer	0.00033	0.00305	CcSEcCtD
Darifenacin—Cough—Methotrexate—bone cancer	0.000327	0.00302	CcSEcCtD
Darifenacin—Mental disorder—Doxorubicin—bone cancer	0.000326	0.00302	CcSEcCtD
Darifenacin—Flatulence—Doxorubicin—bone cancer	0.000319	0.00295	CcSEcCtD
Darifenacin—Arthralgia—Methotrexate—bone cancer	0.000319	0.00295	CcSEcCtD
Darifenacin—Dysgeusia—Doxorubicin—bone cancer	0.000317	0.00293	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000317	0.00293	CcSEcCtD
Darifenacin—Syncope—Epirubicin—bone cancer	0.000314	0.0029	CcSEcCtD
Darifenacin—Back pain—Doxorubicin—bone cancer	0.000314	0.0029	CcSEcCtD
Darifenacin—Palpitations—Epirubicin—bone cancer	0.00031	0.00286	CcSEcCtD
Darifenacin—Confusional state—Methotrexate—bone cancer	0.000308	0.00285	CcSEcCtD
Darifenacin—Loss of consciousness—Epirubicin—bone cancer	0.000308	0.00285	CcSEcCtD
Darifenacin—Cough—Epirubicin—bone cancer	0.000306	0.00283	CcSEcCtD
Darifenacin—Anaphylactic shock—Methotrexate—bone cancer	0.000306	0.00282	CcSEcCtD
Darifenacin—Vision blurred—Doxorubicin—bone cancer	0.000305	0.00282	CcSEcCtD
Darifenacin—Infection—Methotrexate—bone cancer	0.000304	0.00281	CcSEcCtD
Darifenacin—Hypertension—Epirubicin—bone cancer	0.000302	0.0028	CcSEcCtD
Darifenacin—Nervous system disorder—Methotrexate—bone cancer	0.0003	0.00277	CcSEcCtD
Darifenacin—Arthralgia—Epirubicin—bone cancer	0.000298	0.00276	CcSEcCtD
Darifenacin—Skin disorder—Methotrexate—bone cancer	0.000297	0.00274	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000296	0.00274	CcSEcCtD
Darifenacin—Hyperhidrosis—Methotrexate—bone cancer	0.000295	0.00273	CcSEcCtD
Darifenacin—Clotrimazole—CYP3A4—bone cancer	0.000294	0.306	CrCbGaD
Darifenacin—Dry mouth—Epirubicin—bone cancer	0.000292	0.0027	CcSEcCtD
Darifenacin—Syncope—Doxorubicin—bone cancer	0.000291	0.00269	CcSEcCtD
Darifenacin—Confusional state—Epirubicin—bone cancer	0.000288	0.00266	CcSEcCtD
Darifenacin—Palpitations—Doxorubicin—bone cancer	0.000286	0.00265	CcSEcCtD
Darifenacin—Oedema—Epirubicin—bone cancer	0.000286	0.00264	CcSEcCtD
Darifenacin—Anaphylactic shock—Epirubicin—bone cancer	0.000286	0.00264	CcSEcCtD
Darifenacin—Loss of consciousness—Doxorubicin—bone cancer	0.000285	0.00263	CcSEcCtD
Darifenacin—Infection—Epirubicin—bone cancer	0.000284	0.00263	CcSEcCtD
Darifenacin—Cough—Doxorubicin—bone cancer	0.000283	0.00261	CcSEcCtD
Darifenacin—Shock—Epirubicin—bone cancer	0.000281	0.0026	CcSEcCtD
Darifenacin—Nervous system disorder—Epirubicin—bone cancer	0.00028	0.00259	CcSEcCtD
Darifenacin—Hypertension—Doxorubicin—bone cancer	0.00028	0.00259	CcSEcCtD
Darifenacin—Tachycardia—Epirubicin—bone cancer	0.000279	0.00258	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000278	0.00257	CcSEcCtD
Darifenacin—Skin disorder—Epirubicin—bone cancer	0.000278	0.00257	CcSEcCtD
Darifenacin—Hyperhidrosis—Epirubicin—bone cancer	0.000276	0.00255	CcSEcCtD
Darifenacin—Insomnia—Methotrexate—bone cancer	0.000276	0.00255	CcSEcCtD
Darifenacin—Arthralgia—Doxorubicin—bone cancer	0.000276	0.00255	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000274	0.00253	CcSEcCtD
Darifenacin—Dyspnoea—Methotrexate—bone cancer	0.000272	0.00252	CcSEcCtD
Darifenacin—Somnolence—Methotrexate—bone cancer	0.000272	0.00251	CcSEcCtD
Darifenacin—Dry mouth—Doxorubicin—bone cancer	0.00027	0.00249	CcSEcCtD
Darifenacin—Dyspepsia—Methotrexate—bone cancer	0.000269	0.00249	CcSEcCtD
Darifenacin—Confusional state—Doxorubicin—bone cancer	0.000267	0.00247	CcSEcCtD
Darifenacin—Anaphylactic shock—Doxorubicin—bone cancer	0.000265	0.00245	CcSEcCtD
Darifenacin—Oedema—Doxorubicin—bone cancer	0.000265	0.00245	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Methotrexate—bone cancer	0.000264	0.00244	CcSEcCtD
Darifenacin—Infection—Doxorubicin—bone cancer	0.000263	0.00243	CcSEcCtD
Darifenacin—Pain—Methotrexate—bone cancer	0.000261	0.00241	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Epirubicin—bone cancer	0.00026	0.00241	CcSEcCtD
Darifenacin—Shock—Doxorubicin—bone cancer	0.00026	0.00241	CcSEcCtD
Darifenacin—Nervous system disorder—Doxorubicin—bone cancer	0.000259	0.0024	CcSEcCtD
Darifenacin—Insomnia—Epirubicin—bone cancer	0.000259	0.00239	CcSEcCtD
Darifenacin—Tachycardia—Doxorubicin—bone cancer	0.000258	0.00239	CcSEcCtD
Darifenacin—Skin disorder—Doxorubicin—bone cancer	0.000257	0.00237	CcSEcCtD
Darifenacin—Hyperhidrosis—Doxorubicin—bone cancer	0.000256	0.00236	CcSEcCtD
Darifenacin—Dyspnoea—Epirubicin—bone cancer	0.000255	0.00236	CcSEcCtD
Darifenacin—Somnolence—Epirubicin—bone cancer	0.000254	0.00235	CcSEcCtD
Darifenacin—Feeling abnormal—Methotrexate—bone cancer	0.000252	0.00233	CcSEcCtD
Darifenacin—Dyspepsia—Epirubicin—bone cancer	0.000252	0.00233	CcSEcCtD
Darifenacin—Fentanyl—CYP3A4—bone cancer	0.000251	0.262	CrCbGaD
Darifenacin—Gastrointestinal pain—Methotrexate—bone cancer	0.00025	0.00231	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Epirubicin—bone cancer	0.000247	0.00228	CcSEcCtD
Darifenacin—Constipation—Epirubicin—bone cancer	0.000244	0.00226	CcSEcCtD
Darifenacin—Pain—Epirubicin—bone cancer	0.000244	0.00226	CcSEcCtD
Darifenacin—Loperamide—CYP3A4—bone cancer	0.000242	0.252	CrCbGaD
Darifenacin—Abdominal pain—Methotrexate—bone cancer	0.000242	0.00223	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000241	0.00223	CcSEcCtD
Darifenacin—Insomnia—Doxorubicin—bone cancer	0.000239	0.00221	CcSEcCtD
Darifenacin—Dyspnoea—Doxorubicin—bone cancer	0.000236	0.00218	CcSEcCtD
Darifenacin—Feeling abnormal—Epirubicin—bone cancer	0.000236	0.00218	CcSEcCtD
Darifenacin—Somnolence—Doxorubicin—bone cancer	0.000235	0.00217	CcSEcCtD
Darifenacin—Gastrointestinal pain—Epirubicin—bone cancer	0.000234	0.00216	CcSEcCtD
Darifenacin—Dyspepsia—Doxorubicin—bone cancer	0.000233	0.00215	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000228	0.00211	CcSEcCtD
Darifenacin—Pain—Doxorubicin—bone cancer	0.000226	0.00209	CcSEcCtD
Darifenacin—Constipation—Doxorubicin—bone cancer	0.000226	0.00209	CcSEcCtD
Darifenacin—Abdominal pain—Epirubicin—bone cancer	0.000226	0.00209	CcSEcCtD
Darifenacin—Hypersensitivity—Methotrexate—bone cancer	0.000225	0.00208	CcSEcCtD
Darifenacin—Asthenia—Methotrexate—bone cancer	0.000219	0.00203	CcSEcCtD
Darifenacin—Feeling abnormal—Doxorubicin—bone cancer	0.000218	0.00201	CcSEcCtD
Darifenacin—Gastrointestinal pain—Doxorubicin—bone cancer	0.000216	0.002	CcSEcCtD
Darifenacin—Pruritus—Methotrexate—bone cancer	0.000216	0.002	CcSEcCtD
Darifenacin—Hypersensitivity—Epirubicin—bone cancer	0.000211	0.00195	CcSEcCtD
Darifenacin—Abdominal pain—Doxorubicin—bone cancer	0.000209	0.00193	CcSEcCtD
Darifenacin—Diarrhoea—Methotrexate—bone cancer	0.000209	0.00193	CcSEcCtD
Darifenacin—Asthenia—Epirubicin—bone cancer	0.000205	0.0019	CcSEcCtD
Darifenacin—Pruritus—Epirubicin—bone cancer	0.000202	0.00187	CcSEcCtD
Darifenacin—Dizziness—Methotrexate—bone cancer	0.000202	0.00187	CcSEcCtD
Darifenacin—Diarrhoea—Epirubicin—bone cancer	0.000196	0.00181	CcSEcCtD
Darifenacin—Hypersensitivity—Doxorubicin—bone cancer	0.000195	0.0018	CcSEcCtD
Darifenacin—Vomiting—Methotrexate—bone cancer	0.000194	0.0018	CcSEcCtD
Darifenacin—Rash—Methotrexate—bone cancer	0.000193	0.00178	CcSEcCtD
Darifenacin—Dermatitis—Methotrexate—bone cancer	0.000192	0.00178	CcSEcCtD
Darifenacin—Headache—Methotrexate—bone cancer	0.000191	0.00177	CcSEcCtD
Darifenacin—Asthenia—Doxorubicin—bone cancer	0.00019	0.00175	CcSEcCtD
Darifenacin—Dizziness—Epirubicin—bone cancer	0.000189	0.00175	CcSEcCtD
Darifenacin—Pruritus—Doxorubicin—bone cancer	0.000187	0.00173	CcSEcCtD
Darifenacin—Vomiting—Epirubicin—bone cancer	0.000182	0.00168	CcSEcCtD
Darifenacin—Nausea—Methotrexate—bone cancer	0.000181	0.00168	CcSEcCtD
Darifenacin—Diarrhoea—Doxorubicin—bone cancer	0.000181	0.00167	CcSEcCtD
Darifenacin—Rash—Epirubicin—bone cancer	0.00018	0.00167	CcSEcCtD
Darifenacin—Dermatitis—Epirubicin—bone cancer	0.00018	0.00166	CcSEcCtD
Darifenacin—Headache—Epirubicin—bone cancer	0.000179	0.00166	CcSEcCtD
Darifenacin—Dizziness—Doxorubicin—bone cancer	0.000175	0.00162	CcSEcCtD
Darifenacin—Methadone—CYP3A4—bone cancer	0.000172	0.18	CrCbGaD
Darifenacin—Nausea—Epirubicin—bone cancer	0.00017	0.00157	CcSEcCtD
Darifenacin—Vomiting—Doxorubicin—bone cancer	0.000168	0.00155	CcSEcCtD
Darifenacin—Rash—Doxorubicin—bone cancer	0.000167	0.00154	CcSEcCtD
Darifenacin—Dermatitis—Doxorubicin—bone cancer	0.000167	0.00154	CcSEcCtD
Darifenacin—Headache—Doxorubicin—bone cancer	0.000166	0.00153	CcSEcCtD
Darifenacin—Nausea—Doxorubicin—bone cancer	0.000157	0.00145	CcSEcCtD
Darifenacin—CYP2D6—Oxidation by Cytochrome P450—CYP4V2—bone cancer	1.96e-06	0.0363	CbGpPWpGaD
Darifenacin—CHRM2—SIDS Susceptibility Pathways—FEV—bone cancer	1.53e-06	0.0283	CbGpPWpGaD
Darifenacin—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	1.28e-06	0.0237	CbGpPWpGaD
Darifenacin—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	1.2e-06	0.0223	CbGpPWpGaD
Darifenacin—CYP2D6—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	1.13e-06	0.0209	CbGpPWpGaD
Darifenacin—CYP2D6—Xenobiotics—CYP3A4—bone cancer	9.44e-07	0.0175	CbGpPWpGaD
Darifenacin—CHRM4—Calcium Regulation in the Cardiac Cell—RGS1—bone cancer	9.3e-07	0.0172	CbGpPWpGaD
Darifenacin—CYP2D6—Tamoxifen metabolism—CYP3A4—bone cancer	9.08e-07	0.0168	CbGpPWpGaD
Darifenacin—CHRM5—Calcium Regulation in the Cardiac Cell—RGS1—bone cancer	8.91e-07	0.0165	CbGpPWpGaD
Darifenacin—CYP2D6—Metapathway biotransformation—CYP4V2—bone cancer	8.42e-07	0.0156	CbGpPWpGaD
Darifenacin—CHRM1—Circadian rythm related genes—TNFRSF11A—bone cancer	8.15e-07	0.0151	CbGpPWpGaD
Darifenacin—CHRM3—GPCRs, Other—GRM1—bone cancer	8.04e-07	0.0149	CbGpPWpGaD
Darifenacin—CHRM2—GPCRs, Other—GRM1—bone cancer	7.96e-07	0.0148	CbGpPWpGaD
Darifenacin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	6.91e-07	0.0128	CbGpPWpGaD
Darifenacin—CHRM4—G alpha (i) signalling events—GRM4—bone cancer	6.46e-07	0.012	CbGpPWpGaD
Darifenacin—CHRM4—G alpha (i) signalling events—RGS1—bone cancer	6.46e-07	0.012	CbGpPWpGaD
Darifenacin—CHRM5—G alpha (q) signalling events—GRM1—bone cancer	6.44e-07	0.0119	CbGpPWpGaD
Darifenacin—CHRM1—Calcium Regulation in the Cardiac Cell—RGS1—bone cancer	6.27e-07	0.0116	CbGpPWpGaD
Darifenacin—CHRM3—Calcium Regulation in the Cardiac Cell—RGS1—bone cancer	6.25e-07	0.0116	CbGpPWpGaD
Darifenacin—CHRM2—Calcium Regulation in the Cardiac Cell—RGS1—bone cancer	6.19e-07	0.0115	CbGpPWpGaD
Darifenacin—CHRM3—Regulation of insulin secretion—GNA11—bone cancer	5.92e-07	0.011	CbGpPWpGaD
Darifenacin—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—GRM1—bone cancer	5.76e-07	0.0107	CbGpPWpGaD
Darifenacin—CHRM3—GPCRs, Other—SMO—bone cancer	5.67e-07	0.0105	CbGpPWpGaD
Darifenacin—CHRM2—GPCRs, Other—SMO—bone cancer	5.61e-07	0.0104	CbGpPWpGaD
Darifenacin—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	5.5e-07	0.0102	CbGpPWpGaD
Darifenacin—CHRM4—Calcium Regulation in the Cardiac Cell—GNA11—bone cancer	5.2e-07	0.00963	CbGpPWpGaD
Darifenacin—CHRM5—Calcium Regulation in the Cardiac Cell—GNA11—bone cancer	4.98e-07	0.00922	CbGpPWpGaD
Darifenacin—CHRM3—Integration of energy metabolism—GNA11—bone cancer	4.66e-07	0.00863	CbGpPWpGaD
Darifenacin—CHRM1—G alpha (q) signalling events—GRM1—bone cancer	4.53e-07	0.0084	CbGpPWpGaD
Darifenacin—CHRM3—G alpha (q) signalling events—GRM1—bone cancer	4.52e-07	0.00838	CbGpPWpGaD
Darifenacin—CHRM2—G alpha (i) signalling events—GRM4—bone cancer	4.3e-07	0.00797	CbGpPWpGaD
Darifenacin—CHRM2—G alpha (i) signalling events—RGS1—bone cancer	4.3e-07	0.00797	CbGpPWpGaD
Darifenacin—CHRM5—G alpha (q) signalling events—GNA11—bone cancer	4.15e-07	0.00769	CbGpPWpGaD
Darifenacin—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—GRM1—bone cancer	4.05e-07	0.00752	CbGpPWpGaD
Darifenacin—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—GRM1—bone cancer	4.04e-07	0.00749	CbGpPWpGaD
Darifenacin—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	3.92e-07	0.00727	CbGpPWpGaD
Darifenacin—CHRM4—GPCR ligand binding—GRM4—bone cancer	3.91e-07	0.00725	CbGpPWpGaD
Darifenacin—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	3.87e-07	0.00717	CbGpPWpGaD
Darifenacin—CHRM5—GPCR ligand binding—GRM4—bone cancer	3.75e-07	0.00694	CbGpPWpGaD
Darifenacin—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	3.71e-07	0.00688	CbGpPWpGaD
Darifenacin—CHRM1—Calcium Regulation in the Cardiac Cell—GNA11—bone cancer	3.5e-07	0.0065	CbGpPWpGaD
Darifenacin—CHRM3—Calcium Regulation in the Cardiac Cell—GNA11—bone cancer	3.49e-07	0.00647	CbGpPWpGaD
Darifenacin—CHRM2—Calcium Regulation in the Cardiac Cell—GNA11—bone cancer	3.46e-07	0.00641	CbGpPWpGaD
Darifenacin—CHRM4—GPCR ligand binding—GRM1—bone cancer	3.39e-07	0.00629	CbGpPWpGaD
Darifenacin—CHRM5—GPCR ligand binding—GRM1—bone cancer	3.25e-07	0.00602	CbGpPWpGaD
Darifenacin—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	3.18e-07	0.00589	CbGpPWpGaD
Darifenacin—CHRM1—G alpha (q) signalling events—GNA11—bone cancer	2.92e-07	0.00542	CbGpPWpGaD
Darifenacin—CHRM3—G alpha (q) signalling events—GNA11—bone cancer	2.91e-07	0.0054	CbGpPWpGaD
Darifenacin—CHRM1—Circadian rythm related genes—GNA11—bone cancer	2.76e-07	0.00511	CbGpPWpGaD
Darifenacin—CHRM1—Circadian rythm related genes—EZH2—bone cancer	2.75e-07	0.00509	CbGpPWpGaD
Darifenacin—CHRM1—GPCR ligand binding—GRM4—bone cancer	2.64e-07	0.00489	CbGpPWpGaD
Darifenacin—CHRM3—GPCR ligand binding—GRM4—bone cancer	2.63e-07	0.00487	CbGpPWpGaD
Darifenacin—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	2.61e-07	0.00484	CbGpPWpGaD
Darifenacin—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	2.6e-07	0.00483	CbGpPWpGaD
Darifenacin—CHRM2—GPCR ligand binding—GRM4—bone cancer	2.6e-07	0.00483	CbGpPWpGaD
Darifenacin—CHRM4—Regulation of Actin Cytoskeleton—BRAF—bone cancer	2.58e-07	0.00479	CbGpPWpGaD
Darifenacin—CHRM5—Regulation of Actin Cytoskeleton—BRAF—bone cancer	2.47e-07	0.00459	CbGpPWpGaD
Darifenacin—CHRM4—GPCR ligand binding—SMO—bone cancer	2.39e-07	0.00443	CbGpPWpGaD
Darifenacin—CHRM5—GPCR ligand binding—SMO—bone cancer	2.29e-07	0.00424	CbGpPWpGaD
Darifenacin—CHRM1—GPCR ligand binding—GRM1—bone cancer	2.29e-07	0.00424	CbGpPWpGaD
Darifenacin—CHRM3—GPCR ligand binding—GRM1—bone cancer	2.28e-07	0.00423	CbGpPWpGaD
Darifenacin—CHRM2—GPCR ligand binding—GRM1—bone cancer	2.26e-07	0.00418	CbGpPWpGaD
Darifenacin—CHRM4—GPCR downstream signaling—RGS1—bone cancer	2.21e-07	0.0041	CbGpPWpGaD
Darifenacin—CHRM4—GPCR downstream signaling—GRM4—bone cancer	2.21e-07	0.0041	CbGpPWpGaD
Darifenacin—CHRM5—GPCR downstream signaling—GRM4—bone cancer	2.12e-07	0.00392	CbGpPWpGaD
Darifenacin—CHRM5—GPCR downstream signaling—RGS1—bone cancer	2.12e-07	0.00392	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—GRM4—bone cancer	2.01e-07	0.00372	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—RGS1—bone cancer	2.01e-07	0.00372	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—RGS1—bone cancer	1.92e-07	0.00356	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—GRM4—bone cancer	1.92e-07	0.00356	CbGpPWpGaD
Darifenacin—CHRM4—GPCR downstream signaling—GRM1—bone cancer	1.92e-07	0.00355	CbGpPWpGaD
Darifenacin—CHRM5—GPCR downstream signaling—GRM1—bone cancer	1.84e-07	0.0034	CbGpPWpGaD
Darifenacin—CHRM1—Regulation of Actin Cytoskeleton—BRAF—bone cancer	1.74e-07	0.00323	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—GRM1—bone cancer	1.74e-07	0.00323	CbGpPWpGaD
Darifenacin—CHRM3—Regulation of Actin Cytoskeleton—BRAF—bone cancer	1.74e-07	0.00322	CbGpPWpGaD
Darifenacin—CHRM2—Regulation of Actin Cytoskeleton—BRAF—bone cancer	1.72e-07	0.00319	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—NDUFA12—bone cancer	1.69e-07	0.00314	CbGpPWpGaD
Darifenacin—CYP2D6—Biological oxidations—CYP3A4—bone cancer	1.69e-07	0.00313	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—GRM1—bone cancer	1.67e-07	0.00309	CbGpPWpGaD
Darifenacin—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	1.66e-07	0.00309	CbGpPWpGaD
Darifenacin—CHRM1—GPCR ligand binding—SMO—bone cancer	1.61e-07	0.00299	CbGpPWpGaD
Darifenacin—CHRM3—GPCR ligand binding—SMO—bone cancer	1.61e-07	0.00298	CbGpPWpGaD
Darifenacin—CHRM2—GPCR ligand binding—SMO—bone cancer	1.59e-07	0.00295	CbGpPWpGaD
Darifenacin—CHRM1—Circadian rythm related genes—CDK4—bone cancer	1.55e-07	0.00287	CbGpPWpGaD
Darifenacin—CHRM1—GPCR downstream signaling—RGS1—bone cancer	1.49e-07	0.00276	CbGpPWpGaD
Darifenacin—CHRM1—GPCR downstream signaling—GRM4—bone cancer	1.49e-07	0.00276	CbGpPWpGaD
Darifenacin—CHRM3—GPCR downstream signaling—GRM4—bone cancer	1.49e-07	0.00275	CbGpPWpGaD
Darifenacin—CHRM3—GPCR downstream signaling—RGS1—bone cancer	1.49e-07	0.00275	CbGpPWpGaD
Darifenacin—CHRM4—Regulation of Actin Cytoskeleton—EGFR—bone cancer	1.48e-07	0.00274	CbGpPWpGaD
Darifenacin—CHRM2—GPCR downstream signaling—GRM4—bone cancer	1.47e-07	0.00273	CbGpPWpGaD
Darifenacin—CHRM2—GPCR downstream signaling—RGS1—bone cancer	1.47e-07	0.00273	CbGpPWpGaD
Darifenacin—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	1.46e-07	0.0027	CbGpPWpGaD
Darifenacin—CYP2D6—Biological oxidations—GSTP1—bone cancer	1.44e-07	0.00268	CbGpPWpGaD
Darifenacin—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	1.42e-07	0.00264	CbGpPWpGaD
Darifenacin—CHRM5—Regulation of Actin Cytoskeleton—EGFR—bone cancer	1.42e-07	0.00263	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—NT5C3A—bone cancer	1.4e-07	0.0026	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—RGS1—bone cancer	1.35e-07	0.00251	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—GRM4—bone cancer	1.35e-07	0.00251	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—RGS1—bone cancer	1.35e-07	0.0025	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—GRM4—bone cancer	1.35e-07	0.0025	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—GRM4—bone cancer	1.34e-07	0.00248	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—RGS1—bone cancer	1.34e-07	0.00248	CbGpPWpGaD
Darifenacin—CHRM1—GPCR downstream signaling—GRM1—bone cancer	1.29e-07	0.0024	CbGpPWpGaD
Darifenacin—CHRM3—GPCR downstream signaling—GRM1—bone cancer	1.29e-07	0.00239	CbGpPWpGaD
Darifenacin—CHRM2—GPCR downstream signaling—GRM1—bone cancer	1.28e-07	0.00236	CbGpPWpGaD
Darifenacin—CHRM4—GPCR downstream signaling—GNA11—bone cancer	1.23e-07	0.00229	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—SMO—bone cancer	1.23e-07	0.00227	CbGpPWpGaD
Darifenacin—CHRM2—SIDS Susceptibility Pathways—JUN—bone cancer	1.21e-07	0.00224	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—GRM4—bone cancer	1.19e-07	0.0022	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—RGS1—bone cancer	1.19e-07	0.0022	CbGpPWpGaD
Darifenacin—CHRM5—GPCR downstream signaling—GNA11—bone cancer	1.18e-07	0.00219	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—SMO—bone cancer	1.17e-07	0.00218	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—GRM1—bone cancer	1.17e-07	0.00218	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—GRM1—bone cancer	1.17e-07	0.00217	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—GRM1—bone cancer	1.16e-07	0.00215	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—GRM4—bone cancer	1.14e-07	0.0021	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—RGS1—bone cancer	1.14e-07	0.0021	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—GNA11—bone cancer	1.12e-07	0.00208	CbGpPWpGaD
Darifenacin—CHRM4—GPCR downstream signaling—IL3—bone cancer	1.12e-07	0.00208	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—GNA11—bone cancer	1.07e-07	0.00199	CbGpPWpGaD
Darifenacin—CHRM5—GPCR downstream signaling—IL3—bone cancer	1.07e-07	0.00199	CbGpPWpGaD
Darifenacin—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	1.06e-07	0.00196	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—GRM1—bone cancer	1.03e-07	0.00191	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—IL3—bone cancer	1.02e-07	0.00188	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—NDUFA12—bone cancer	1.01e-07	0.00188	CbGpPWpGaD
Darifenacin—CHRM1—Circadian rythm related genes—JUN—bone cancer	9.99e-08	0.00185	CbGpPWpGaD
Darifenacin—CHRM1—Regulation of Actin Cytoskeleton—EGFR—bone cancer	9.98e-08	0.00185	CbGpPWpGaD
Darifenacin—CHRM3—Regulation of Actin Cytoskeleton—EGFR—bone cancer	9.94e-08	0.00184	CbGpPWpGaD
Darifenacin—CHRM2—Regulation of Actin Cytoskeleton—EGFR—bone cancer	9.85e-08	0.00183	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—GRM1—bone cancer	9.84e-08	0.00182	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—IL3—bone cancer	9.74e-08	0.0018	CbGpPWpGaD
Darifenacin—CYP3A4—Biological oxidations—GSTP1—bone cancer	9.44e-08	0.00175	CbGpPWpGaD
Darifenacin—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	9.31e-08	0.00173	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—NT5C3A—bone cancer	8.38e-08	0.00155	CbGpPWpGaD
Darifenacin—CHRM1—GPCR downstream signaling—GNA11—bone cancer	8.33e-08	0.00154	CbGpPWpGaD
Darifenacin—CHRM3—GPCR downstream signaling—GNA11—bone cancer	8.3e-08	0.00154	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—SMO—bone cancer	8.27e-08	0.00153	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—SMO—bone cancer	8.24e-08	0.00153	CbGpPWpGaD
Darifenacin—CHRM2—GPCR downstream signaling—GNA11—bone cancer	8.22e-08	0.00152	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—SMO—bone cancer	8.16e-08	0.00151	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—GRM4—bone cancer	7.99e-08	0.00148	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—RGS1—bone cancer	7.99e-08	0.00148	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—RGS1—bone cancer	7.97e-08	0.00148	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—GRM4—bone cancer	7.97e-08	0.00148	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—GRM4—bone cancer	7.89e-08	0.00146	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—RGS1—bone cancer	7.89e-08	0.00146	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—GNA11—bone cancer	7.56e-08	0.0014	CbGpPWpGaD
Darifenacin—CHRM1—GPCR downstream signaling—IL3—bone cancer	7.55e-08	0.0014	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—GNA11—bone cancer	7.54e-08	0.0014	CbGpPWpGaD
Darifenacin—CHRM3—GPCR downstream signaling—IL3—bone cancer	7.52e-08	0.00139	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—GNA11—bone cancer	7.46e-08	0.00138	CbGpPWpGaD
Darifenacin—CHRM2—GPCR downstream signaling—IL3—bone cancer	7.45e-08	0.00138	CbGpPWpGaD
Darifenacin—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	7.44e-08	0.00138	CbGpPWpGaD
Darifenacin—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	7.42e-08	0.00137	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—SMO—bone cancer	7.24e-08	0.00134	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—SMO—bone cancer	6.94e-08	0.00129	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—GRM1—bone cancer	6.93e-08	0.00128	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—GRM1—bone cancer	6.91e-08	0.00128	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—IL3—bone cancer	6.85e-08	0.00127	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—GRM1—bone cancer	6.84e-08	0.00127	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—IL3—bone cancer	6.83e-08	0.00127	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—IL3—bone cancer	6.77e-08	0.00125	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—GNA11—bone cancer	6.62e-08	0.00123	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—NDUFA12—bone cancer	6.61e-08	0.00123	CbGpPWpGaD
Darifenacin—CHRM1—Circadian rythm related genes—TP53—bone cancer	6.59e-08	0.00122	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—GNA11—bone cancer	6.34e-08	0.00118	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—ATF1—bone cancer	6.16e-08	0.00114	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—ENO2—bone cancer	6.14e-08	0.00114	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—IL3—bone cancer	6.01e-08	0.00111	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—ATF1—bone cancer	5.9e-08	0.00109	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—IL3—bone cancer	5.75e-08	0.00107	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—DHFR—bone cancer	5.7e-08	0.00106	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—NT5C3A—bone cancer	5.48e-08	0.00102	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—GNA11—bone cancer	5.32e-08	0.000987	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—TGFBR2—bone cancer	5.14e-08	0.000952	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—TGFBR2—bone cancer	4.92e-08	0.000912	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—SMO—bone cancer	4.88e-08	0.000905	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—SMO—bone cancer	4.87e-08	0.000902	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—IGF1R—bone cancer	4.83e-08	0.000896	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—CYP3A4—bone cancer	4.83e-08	0.000895	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—SMO—bone cancer	4.82e-08	0.000894	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—IGF1R—bone cancer	4.63e-08	0.000858	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—GNA11—bone cancer	4.47e-08	0.000828	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—GNA11—bone cancer	4.45e-08	0.000825	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—GNA11—bone cancer	4.41e-08	0.000817	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—ATF1—bone cancer	4.15e-08	0.00077	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—ATF1—bone cancer	4.14e-08	0.000767	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—GSTP1—bone cancer	4.13e-08	0.000765	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—ATF1—bone cancer	4.1e-08	0.00076	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—IL3—bone cancer	4.05e-08	0.000751	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—IL3—bone cancer	4.04e-08	0.000748	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—IL3—bone cancer	4e-08	0.000741	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—ENO2—bone cancer	3.67e-08	0.000681	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—KIT—bone cancer	3.5e-08	0.00065	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—TGFBR2—bone cancer	3.46e-08	0.000642	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—TGFBR2—bone cancer	3.45e-08	0.00064	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—TGFBR2—bone cancer	3.42e-08	0.000634	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—DHFR—bone cancer	3.41e-08	0.000632	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—KIT—bone cancer	3.36e-08	0.000622	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—BRAF—bone cancer	3.29e-08	0.000611	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—IGF1R—bone cancer	3.26e-08	0.000604	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—IGF1R—bone cancer	3.25e-08	0.000602	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—IGF1R—bone cancer	3.22e-08	0.000596	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—EGFR—bone cancer	3.19e-08	0.000592	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—GNA11—bone cancer	3.18e-08	0.00059	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—BRAF—bone cancer	3.15e-08	0.000585	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—EGFR—bone cancer	3.06e-08	0.000567	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—CYP3A4—bone cancer	2.89e-08	0.000535	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—MDM2—bone cancer	2.76e-08	0.000512	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—MDM2—bone cancer	2.64e-08	0.00049	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—GSTP1—bone cancer	2.47e-08	0.000458	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—ENO2—bone cancer	2.4e-08	0.000445	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—JUN—bone cancer	2.4e-08	0.000445	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—KIT—bone cancer	2.36e-08	0.000438	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—KIT—bone cancer	2.36e-08	0.000437	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—MMP9—bone cancer	2.33e-08	0.000433	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—KIT—bone cancer	2.33e-08	0.000432	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—JUN—bone cancer	2.3e-08	0.000426	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—MMP9—bone cancer	2.24e-08	0.000414	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—DHFR—bone cancer	2.23e-08	0.000413	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—BRAF—bone cancer	2.22e-08	0.000412	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—BRAF—bone cancer	2.21e-08	0.00041	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—BRAF—bone cancer	2.19e-08	0.000406	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—EGFR—bone cancer	2.15e-08	0.000399	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—EGFR—bone cancer	2.15e-08	0.000398	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—PTGS2—bone cancer	2.14e-08	0.000397	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—EGFR—bone cancer	2.13e-08	0.000394	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—GNA11—bone cancer	2.08e-08	0.000386	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—EGFR—bone cancer	1.89e-08	0.00035	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—MDM2—bone cancer	1.86e-08	0.000345	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—MDM2—bone cancer	1.86e-08	0.000344	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—MDM2—bone cancer	1.84e-08	0.000341	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—EGFR—bone cancer	1.81e-08	0.000335	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—JUN—bone cancer	1.62e-08	0.0003	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—GSTP1—bone cancer	1.61e-08	0.000299	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—JUN—bone cancer	1.61e-08	0.000299	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—JUN—bone cancer	1.6e-08	0.000296	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—TP53—bone cancer	1.58e-08	0.000294	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—MMP9—bone cancer	1.57e-08	0.000292	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—MMP9—bone cancer	1.57e-08	0.000291	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—MMP9—bone cancer	1.55e-08	0.000288	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—TP53—bone cancer	1.52e-08	0.000281	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—PTGS2—bone cancer	1.28e-08	0.000237	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—EGFR—bone cancer	1.27e-08	0.000236	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—EGFR—bone cancer	1.27e-08	0.000235	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—EGFR—bone cancer	1.26e-08	0.000233	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—TP53—bone cancer	1.07e-08	0.000198	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—TP53—bone cancer	1.06e-08	0.000197	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—TP53—bone cancer	1.05e-08	0.000195	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—PTGS2—bone cancer	8.36e-09	0.000155	CbGpPWpGaD
